White House Estimated $64 Billion in Medicaid Savings
The GENEROUS model aims to lower state drug costs through international price benchmarks, impacting how public health budgets are managed.
Updated on Oct. 7, 2026 in Healthcare
Live Poll
Do you trust the federal government's long-term budget savings projections for healthcare programs?
In early 2026, the White House Council of Economic Advisers projected $64.3 billion in Medicaid prescription drug savings over a ten-year period. The figures stem from the GENEROUS model, a program launched in January 2026 that allows states to secure rebates based on international pricing.
Why it matters
The program seeks to address drug spending, which accounts for 6% of Medicaid expenditures, by implementing most-favored-nation pricing. It shifted the landscape for state healthcare budgeting by attempting to bridge the gap in pricing, though independent reports have questioned the transparency of the underlying estimates.
The CEA estimates $64.3 billion in ten-year savings, with $27.6 billion designated as the state share. This represents roughly a 2% savings against the $325 billion states spent on Medicaid in fiscal 2024.
The players
White House Council of Economic Advisers
The executive branch agency responsible for providing economic analysis and policy guidance.
President Donald Trump
The current President of the United States who oversaw the administration's program projections.
FactCheck.org
A non-partisan project that monitors the factual accuracy of statements made by public officials.
The details
Under the GENEROUS model, drugmakers pay rebates to states based on prices paid in other nations, with the CEA assuming current Medicaid prices are 2.5 times higher than these global benchmarks. States have the discretion to select which specific drugs to include in their program agreements. CMS estimates suggest that these annual rebates could reach $5.2 billion, depending on the breadth of drugs that states choose to cover.
Timeline
The GENEROUS model program launched in January 2026.
States spent $325 billion on Medicaid in fiscal 2024.
President Trump stated on September 18, 2026, that savings could reach $100 billion.
The deadline for states to sign GENEROUS agreements was September 30, 2026.
FactCheck.org published a review of the savings projections on October 5, 2026.
Market Landscape
The GENEROUS model establishes a new framework for federal-state drug pricing negotiations by tying domestic rebates to international market rates. This approach represents a departure from traditional Medicaid rebate structures by targeting the 2.5 multiplier the CEA identifies between current and global prices.
Operators dealing with Medicaid-funded pharmaceuticals should monitor which drugs their state governments include in GENEROUS agreements to gauge potential rebate impacts. Evaluate how these international pricing benchmarks might alter procurement strategies and reimbursement margins in the coming years.
The takeaway
The gap between domestic prices and international benchmarks remains the primary driver of federal savings projections. Business leaders should track official state program updates and CMS guidance to determine which drugs are subject to these rebate models in their specific jurisdictions.
Further reading
For more on evolving drug pricing policies, see the latest updates in Healthcare.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust the federal government's long-term budget savings projections for healthcare programs?
